Hospital Pharmacy Compounding against COVID-19 pandemic

Hospital Pharmacy Compounding against COVID-19 pandemic

As in other areas of the health system, COVID-19 has had a dramatic impact on hospital compounding. This area has faced numerous challenges, including the shortage of frequent-use products (hydroalcoholic solutions, lopinavir/ritonavir suspension), the use of new preparations for SARS-CoV-2 (tocil...

Full description

Bibliographic Details
Main Authors:	José María Alonso-Herreros, Silvia Berisa-Prado, Carme Cañete-Ramírez, María del Pilar Flox-Benítez, Margarita Ladrón de Guevara-García, Carmen López-Cabezas, Ana María Martín de Rosales-Cabrera, Beatriz Ramos-Martínez
Format:	Article
Language:	English
Published:	Grupo Aula Médica 2020-06-01
Series:	Farmacia Hospitalaria
Subjects:	drug compounding hospital pharmacy service covid-19 pandemic lopinavir ritonavir hand hygiene hydroxychloroquine
Online Access:	http://www.aulamedica.es/fh/pdf/11492.pdf

Similar Items

Pharmacological management of COVID-19
by: Veena Raghunathan, et al.
Published: (2020-01-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
by: hasan mohammed altemimy
Published: (2020-06-01)

COVID-19: A Brief Overview of the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-04-01)

COVID-19: An Update About the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-05-01)

The Effect of Proposed Drugs in the Treatment of Patients with COVID- 19: A Systematic Review
by: Amir Shakarami, et al.
Published: (2020-11-01)

A narrative review of antiviral drugs used for COVID-19 pharmacotherapy
by: Subodh Kumar, et al.
Published: (2021-01-01)

Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations
by: Paolo Gaibani, et al.
Published: (2021-03-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
by: Justin T. Denholm, et al.
Published: (2020-07-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
by: Min Joo Choi, et al.
Published: (2021-01-01)

Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
by: Abhi Bhadra, et al.
Published: (2020-05-01)

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
by: Milo Gatti, et al.
Published: (2021-02-01)

Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
by: David Grimaldi, et al.
Published: (2020-10-01)

Battling COVID-19: using old weapons for a new enemy
by: Rohit Kumar, et al.
Published: (2020-05-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021-05-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Şule Özdemir, et al.
Published: (2020-12-01)

Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital
by: Natsuda Aumpan, et al.
Published: (2021-09-01)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
by: Ji-Won Kim, et al.
Published: (2021-03-01)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
by: Katya Uzunova, et al.
Published: (2020-11-01)

COVID-19 possible medical treatments
by: Marzieh Mohammadi, et al.
Published: (2021-01-01)

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial
by: Prasan Kumar Panda, et al.
Published: (2020-10-01)

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
by: Stanković Biljana, et al.
Published: (2020-01-01)

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
by: Cristina Adriana Dehelean, et al.
Published: (2020-07-01)

Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19
by: Panda PK, et al.
Published: (2021-09-01)

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
by: Marie Lecronier, et al.
Published: (2020-07-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV
by: BASAVAPRABHU ACHAPPA, et al.
Published: (2019-01-01)

Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
by: Abubakar AR, et al.
Published: (2020-12-01)

Farmacocinética da co-formulação Lopinavir/ritonavir em forma de comprimidos, em dosagem padrão e dosagem aumentada, em gestantes portadoras do HIV
by: Oliveira, Marilia Santini de.
Published: (2014)

In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses
by: Chang Kyung Kang, et al.
Published: (2020-07-01)

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
by: A. S. Kolbin
Published: (2020-05-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)
by: Gbenga A. Adefolaju, et al.
Published: (2015-11-01)

Comparison of effectiveness of various treatment strategies in COVID-19 patients: A Systematic Review
by: Muhammad Shehryar Hussain, et al.
Published: (2020-08-01)

Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19?
by: Shahnaz Sali, et al.
Published: (2020-12-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir
by: Bengü Şaylan, et al.
Published: (2020-11-01)

Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19
by: Amrit Krishna Mitra
Published: (2020-12-01)

Disposição cinética e transferência placentária do lopinavir e ritonavir em gestantes portadoras do HIV
by: Cestari, Roberta Natália
Published: (2014)